Valuation: Telix Pharmaceuticals Limited

Market Cap 6.07B 4.31B 3.76B 3.55B 3.22B 6.04B 414B 42.52B 16.41B 210B 16.2B 15.84B 677B P/E 2026 *
233x
P/E 2027 * 773x
Enterprise Value 6.5B 4.62B 4.03B 3.8B 3.45B 6.47B 443B 45.55B 17.58B 225B 17.35B 16.96B 725B EV / Sales 2026 *
4.73x
EV / Sales 2027 * 4.19x
Free-Float
83.13%
Yield 2026 *
-
Yield 2027 * -
1 day+1.62%
1 week+4.58%
Current month+13.25%
1 month+5.64%
3 months+25.00%
6 months+48.08%
Current year+62.23%
1 week 11
Extreme 11
13
1 month 10.2
Extreme 10.2
13
Current year 5.91
Extreme 5.91
13
1 year 5.91
Extreme 5.91
13
3 years 5.3
Extreme 5.3
24.85
5 years 2.69
Extreme 2.69
24.85
10 years 0.64
Extreme 0.635
24.85
Manager TitleAgeSince
Chief Executive Officer 51 03/01/2017
Director of Finance/CFO 61 31/07/2022
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member 51 03/01/2017
Chairman 66 03/02/2026
Director/Board Member 68 19/06/2018
Change 5-day change 1-year change 3-year change Capi.($)
+1.62%+4.58% - - 4.31B
+0.11%+2.71%+0.44%+26.85% 46.28B
-1.12%+1.78%+42.30%+27.55% 43.85B
-3.04%-6.29%+338.56%+515.97% 40.93B
-0.74%+1.25%+4.92%+67.98% 39.89B
-0.50%+0.67%+10.29%+41.28% 29.5B
-0.46%+4.22%+22.81%+139.44% 17.09B
-0.97%-10.17% - - 15.55B
-0.57%+8.12%+22.19%+38.68% 15.22B
-3.14%+31.91%-11.79% - 14.05B
Average -0.88%+3.76%+53.72%+122.54% 29.15B
Weighted average by Cap. -1.06%+1.87%+68.04%+130.90%

Financials

2026 *2027 *
Net sales 1.37B 976M 851M 803M 730M 1.37B 93.64B 9.62B 3.71B 47.61B 3.67B 3.58B 153B 1.57B 1.11B 970M 916M 832M 1.56B 107B 10.97B 4.23B 54.28B 4.18B 4.09B 175B
Net income 27.78M 19.75M 17.22M 16.26M 14.77M 27.67M 1.9B 195M 75.17M 964M 74.19M 72.55M 3.1B 1.14M 812K 708K 669K 607K 1.14M 77.94M 8.01M 3.09M 39.63M 3.05M 2.98M 128M
Net Debt 431M 306M 267M 252M 229M 429M 29.41B 3.02B 1.17B 14.95B 1.15B 1.13B 48.11B 491M 349M 304M 287M 261M 488M 33.46B 3.44B 1.33B 17.01B 1.31B 1.28B 54.74B
Logo Telix Pharmaceuticals Limited
Telix Pharmaceuticals Limited is an Australia-based biopharmaceutical company focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals and associated medical technologies. It is developing a portfolio of clinical and commercial stage products that aims to address significant unmet medical needs in oncology and rare diseases. Its segments include Therapeutics, Precision Medicine and Telix Manufacturing Solutions. Therapeutics segment develops targeted radionuclide therapies for urologic, neurologic, musculoskeletal and hematological cancers. Precision Medicine segment focuses on bringing diagnostic imaging solutions to market. Precision Medicine segment also includes MedTech and International businesses. Telix Manufacturing Solutions segment is its global network of facilities designed to deliver patient doses worldwide. Its pipeline products include TLX591, TLX250, TLX101, TLX66, TLX592, TLX252, TLX400, Illuccix (68Ga-PSMA-11) and TLX007-CDx.
Employees
1,152
Date Price Change Volume
18/09/26 $12.55 +1.62% 100
17/09/26 $12.35 +12.27% 2,488
16/09/26 $11.00 -10.13% 61,100
15/09/26 $12.24 +11.17% 6,252
14/09/26 $11.01 -8.25% 304
Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
14
Last Close Price
17.85AUD
Average target price
23.52AUD
Spread / Average Target
+31.78%

Quarterly revenue - Rate of surprise

LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!